Merck buys stake in U.S. biotech firm; drug maker bets on experimental therapies

Article Abstract:

Merck KGaA announced its purchase of a 57% stake in Lexigen Pharmaceuticals Corp., but did not disclose price or terms. Lexigen is a Lexington, Mass.. firm with anticancer therapies that will help Merck's new drug pipeline. Concern is always the cheap generics that pillage profits. Merck's Glucophage will face fate that at the end of 1999. Merck, though, makes generics itself.

United States, Abstract, Merck KGAA, Lexigen Pharmaceuticals Corp.

---

Merck sells stake in marketing deal for 870 million euros

Article Abstract:

Germany-based pharmaceutical maker Merck agreed to sell its 50% stake in a troubled diagnostics venture to Italy-based privately held Bracco Group for 1.7 billion marks (870 million euros).

Italy, Foreign operations, In-Vitro Diagnostic Substance Manufacturing, Anticancer Diagnostics, Pharmaceutical industry, Mergers, acquisitions and divestments, Diagnostic reagents industry, Merck & Company Inc., Cancer diagnostic reagents

---

Similar abstracts:

• Abstracts: Credit Suisse bets on Latin America with Garantia. UBS chairman quits over fund. Credit Suisse confirms talks with Garantia
• Abstracts: Philips sets out to become market leader. Philips will buy ATL for $800 million. Philips investors ask: where next?
• Abstracts: Pearson to sell Tussauds Group to Charterhouse for $597 million. Hotelier Thistle talks to possible bidders
• Abstracts: Thyssen's interest lifts Cockerill. Usinor, Thyssen Krupp chosen to bid for Cockerill. CNP aims to redefine itself but skeptics remain
• Abstracts: Accord brings return of Air France pilots. U.S. still off limits for U.K. carrier

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.